Sera Prognostics (NASDAQ:SERA) Posts Quarterly Earnings Results

Sera Prognostics (NASDAQ:SERA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Zacks reports. The firm had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share.

Sera Prognostics Stock Performance

Sera Prognostics stock traded down $0.14 during mid-day trading on Friday, hitting $3.79. The company's stock had a trading volume of 350,781 shares, compared to its average volume of 140,547. The company has a 50 day moving average of $4.91 and a 200-day moving average of $6.56. The stock has a market cap of $128.00 million, a PE ratio of -3.83 and a beta of 0.89. Sera Prognostics has a one year low of $3.77 and a one year high of $12.36.

Insider Buying and Selling at Sera Prognostics

In other Sera Prognostics news, General Counsel Benjamin Jackson sold 7,912 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $6.38, for a total value of $50,478.56. Following the transaction, the general counsel now owns 120,561 shares of the company's stock, valued at $769,179.18. This represents a 6.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Joshua Phillips sold 12,163 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the completion of the sale, the director now owns 2 shares of the company's stock, valued at $12.78. This represents a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,877 shares of company stock valued at $480,677 in the last quarter. 15.80% of the stock is owned by insiders.

Remove Ads

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.